甲基酸对骨髓增殖性瘤中JAK/ STAT通路的激活的影响
Sally Thomas1, Katherine Fisher2, John Snowden3
1Sheffield Cancer Research Centre, University of Sheffield, Sheffield, UK.
Lancet (London, England)
|August 28, 2015
概括
甲甲酸抑制了JAK/ STAT通路,这是骨髓增殖性瘤的一个关键驱动因素. 这种药物可作为包括骨髓纤维化在内的这些血液癌症的经济有效治疗方法.
科学领域:
- 癌症学
- 血液学
- 药理学
背景情况:
- 骨髓增殖性瘤 (MPN) 是由JAK/ STAT通路激活驱动的血液癌症.
- 在50- 95%的MPN患者中发现了JAK2V617F突变,导致构成性的JAK2激活.
- 目前用于治疗MPN,特别是骨髓纤维化,在疗效和成本方面存在局限性.
研究的目的:
- 确定针对JAK/STAT信号通路的新疗法化合物.
- 探索现有药物作为骨髓增殖性瘤治疗的潜力.
- 寻找用于骨髓纤维化治疗的现有JAK抑制剂的经济有效替代品.
主要方法:
- 在Drosophila模型中使用基于 luciferase的测试对2000个小分子进行了选.
- 通过在HDLM-2细胞中进行西部抹杀验证.
- 在JAK2V617F驱动的HEL细胞系中测试了已识别的化合物的疗效.
主要成果:
- 甲基和阿米诺被确定为Drosophila JAK/ STAT通路的强有力的抑制剂.
- 这种抑制作用在人体细胞中保持.
- 在临床相关的度下,甲甲酸抑制了HEL细胞中的JAK/ STAT激活.
结论:
- 甲托雷克萨特具有作为新型骨髓增殖瘤治疗的潜力.
- 这些发现对肌肉纤维化特别重要,为JAK1/ 2抑制剂提供了潜在的更便宜的替代品.
- 需要进行进一步的临床试验,以评估甲状腺素在患者初级细胞中的疗效.
更多相关视频
相关概念视频
The JAK-STAT Signaling Pathway
14.0K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
14.0K
mTOR Signaling and Cancer Progression
5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression
1.7K
1.7K
MAPK Signaling Cascades
9.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.3K
Interactions Between Signaling Pathways
7.9K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
PI3K/mTOR/AKT Signaling Pathway
6.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.4K


